Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

This Phase I/II trial is testing a new immunotherapy drug called JMT108 for people with advanced or metastatic melanoma (skin cancer) that cannot be surgically removed. **You may be eligible if...** - You are 18 or older - You have locally advanced or metastatic melanoma confirmed by biopsy that cannot be removed surgically - Your melanoma has not responded to previous treatments, or no standard treatment is available - You have at least one measurable tumor on scan - You are in good physical condition (ECOG 0–1) with at least 3 months expected survival - Your organ function is adequate **You may NOT be eligible if...** - You received cancer treatment (chemo, radiation, targeted therapy, immunotherapy) within the past 4 weeks - You have previously received IL-2 or IL-15 cancer therapies - You have active or growing brain metastases (stable brain metastases are allowed) - You have active autoimmune disease - You have had a blood clot (arterial or venous thrombosis) within the past 6 months - You are on systemic steroids or immune-suppressing drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.